For most early-stage biotech companies, revenue is but a far-off dream. They rely mostly on investors’ cash or government funding until they’re advanced enough to market a drug or sign licensing deals with major pharmaceutical companies. But the global economic crisis, which has caused investors to scale back on funding ...
QuatRx Pharmaceuticals' ability to obtain market approval next year for its top drug candidate is tied directly to the Ann Arbor biotech firm's ability to fulfill the increasingly strict expectations of the U.S. Food and Drug Administration, an industry leader said today. Stephen Rapundalo, executive director of Ann Arbor-based MichBio, ...
Ann Arbor biotech firm QuatRx Pharmaceuticals is on track to submit a federal application for approval of its post-menopausal sex drug by early 2010, company officials announced today.Securing the Food and Drug Administration’s approval for Ophena would prove to be a significant accomplishment matched only by a few biotech companies ...
Angela J. Cesere | AnnArbor.com AnnArbor.com's partner news site MLive.com is on a quest to find the best barbecue in ......
Get the Ann Arbor RSS Feed
AnnArbor.com